Navigation Links
Watson Files FDA Applications for Generic Mucinex(R)
Date:4/22/2009

- Paragraph IV Litigation Underway -

CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that it has filed two Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin extended-release 600mg and 1200mg tablets and its dextromethorphan HBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc. Watson's guaifenesin and dextromethorphan HBr/guaifenesin extended-release tablet products are the generic versions of Reckitt Benckiser Inc.'s Mucinex(R) and Mucinex(R) DM products which are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive.

Reckitt Benckiser filed suit against Watson on April 20, 2009 in the U.S. District Court for the Southern District of New York seeking to prevent Watson from commercializing its products prior to expiration of U.S. patent numbers 6,372,252 and 6,955,821. Reckitt Benckiser's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson's ANDAs for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner. Based on available information, Watson believes it may be the first applicant to file an ANDA for a generic version of Mucinex DM(R) and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve-months ended December 31, 2008, Mucinex(R) and Mucinex(R) DM products had total U.S. sales of approximately $106 million and $85 million respectively, according to IMS Health data.

About Wa
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... ... MONTICELLO, Fla. – After completing 2,400 hours in the Clinical Pastoral Education ... a clinician allowed Dr. Barbara Thomas-Reddick to gain the skills and the ... families, friends and staff, and she was able to witness after leaving the patients’ ...
(Date:8/4/2015)... ... ... How cool is it to check in at your favorite place and ... will soon allow you to do just that. , Ahhaa is releasing the next ... feature. , Users will soon get to share what inspires them about their favorite ...
(Date:8/4/2015)... ... August 04, 2015 , ... World Patent Marketing, a ... Rack, a fitness invention that eliminates the need to have a partner or ... Clubs industry is worth $30 billion," says Scott Cooper, CEO and Creative Director ...
(Date:8/4/2015)... ... 04, 2015 , ... The United Nations Foundation today announced ... Indonesia for a select group of U.S.-based journalists during the week of November ... the International Conference on Family Planning in Bali. , In close coordination ...
(Date:8/4/2015)... ... 04, 2015 , ... An article published July 27th by the ... method for encouraging people to lose weight. Specifically the study compared control patients with ... success, adding a financial incentive to the overall incentive of increased health. According to ...
Breaking Medicine News(10 mins):Health News:New book shows how ‘The Presence of a Chaplain’ affects lives 2Health News:New book shows how ‘The Presence of a Chaplain’ affects lives 3Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2
... be linked to abnormalities in a person,s body clock ... published today in the journal Nature Genetics . ... than normal blood sugar levels could partly be tackled ... College London, the French National Research Institute CNRS, Lille ...
... Nurses Association (ONA) and University Hospitals Geneva Medical,Center (University ... on Friday, December 5. To date, the parties have ... At issue are economic provisions including ... has indicated that they will,remove premium rate charts for ...
... a leader in pharmacy,automation, today demonstrated InSite(TM), its ... pharmacies provide unparalleled,support for extended care environments with ... developed in response to hospital pharmacies,increasing need to ... care and correctional care environments they support. , ...
... FRANCISCO, December 7, 2008) The largest study ever ... help prevent deadly blood clots in patients with cancer ... conference on Sunday, December 7, at 9:30 a.m., during ... Hematology in San Francisco, CA. Additional research being featured ...
... 6 The use of dexamethasone early in the treatment ... of childhood cancer, may help reduce the risk of relapse ... on Saturday, December 6, at 2:00 p.m., during the 50th ... Francisco, CA. Additional research will be featured at the press ...
... Cowboy is a new wine that will,help raise money for breast ... Vegas this month. , Purple ... of the,professional rodeo community,s commitment to end breast cancer, it,s a ... Vegas will host the ultimate championship of professional,rodeo -- the Wrangler ...
Cached Medicine News:Health News:Body clock linked to diabetes and high blood sugar in new study 2Health News:Body clock linked to diabetes and high blood sugar in new study 3Health News:University Hospitals Geneva Medical Center Registered Nurses to Strike on December 10 if Contract Agreement Cannot Be Reached 2Health News:Talyst Moves Patient Safety and Inventory Control Beyond the Hospital 2Health News:Talyst Moves Patient Safety and Inventory Control Beyond the Hospital 3Health News:Research highlights new approaches to prevent blood clots 2Health News:Research highlights new approaches to prevent blood clots 3Health News:Research highlights new approaches to prevent blood clots 4Health News:Research highlights new approaches to prevent blood clots 5Health News:Research highlights new approaches to prevent blood clots 6Health News:Research highlights new approaches to prevent blood clots 7Health News:Research highlights new approaches to prevent blood clots 8Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:The Days of Wine and Rodeo 2
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... N.J. , Aug. 4, 2015  ContraVir ... company focused on the development and commercialization of ... , Chief Executive Officer, will present live at ... Thursday, August 6, 2015 TIME: 12:15PM EDT LINK: ... be a live, interactive online event where investors ...
(Date:8/4/2015)... 2015  Syneron Medical Ltd. (NASDAQ: ELOS ), a ... the three month period ended June 30, 2015. ... Highlights: , Revenue of $73.5 million, ... North American product sales grew 45% year-over-year. , International ... 14% product growth in the EMEA region and 25% product ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... 2 HART Health, a national manufacturer and distributor ... service division of Synergy Logistics, a Seattle-based first aid ... new franchise system. Synergy Logistics, Inc. had ... delivery service to mid-sized Seattle businesses since the early ...
... Results from studies related to ... lead developmental product candidate, fidaxomicin, will ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Exhibition Center in Boston on September 12-15, 2010. ...
Cached Medicine Technology:First Aid Supplier HART Health Acquires Competitor and Continues Expansion 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3
...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
Trial lens set +/- Cyl....
...
Medicine Products: